A ROS-responsive TPZ prodrug micelle for co-delivery with doxorubicin in synergistic cancer therapy

Key Points

• Enhanced cancer therapy observed with ROS-responsive prodrug micelles co-delivering doxorubicin.
• Synergistic effects noted, with improved efficacy in targeting cancer cells.
• Assessment using a novel micelle formulation to deliver both TPZ and doxorubicin effectively.
• Findings emphasize the potential for better treatment options in cancer, promoting further investigation.